Author

Young S. Oh 1

1 Genentech, Inc.,South San Francisco,United States of America

A UNITED STATES CLAIMS DATABASE ANALYSIS COMPARING SAFETY, MEDICAL RESOURCE UTILIZATION, AND TREATMENT COSTS ASSOCIATED WITH THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE BY DRUG CLASS

Young S. Oh

A UNITED STATES CLAIMS DATABASE ANALYSIS COMPARING SAFETY, MEDICAL RESOURCE UTILIZATION, AND TREATMENT COSTS ASSOCIATED WITH THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE BY DRUG CLASS

Gráinne H. Long, Amanda R. Tatro, Young S. Oh, Sheila Reiss Reddy, Ashwin N. Ananthakrishnan

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI-TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Laurent Peyrin-Biroulet, Ailsa L Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus Jr, Elham Ostad-Saffari, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William Sandborn

ETROLIZUMAB AS INDUCTION THERAPY IN MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM BERGAMOT COHORT 1

William Sandborn, Julian Panés, Jennifer Jones, Azra Hassanali, Rhian Jacob, Zaineb Sharafali, Young S. Oh, Swati Tole

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

ETROLIZUMAB INDUCTION THERAPY IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: RESULTS FROM THE HICKORY OPEN-LABEL INDUCTION (OLI) TRIAL

Laurent Peyrin-Biroulet, David T. Rubin, Brian G. Feagan, Young S. Oh, Udaysankar Arulmani, Helen Tyrrell, Romeo Maciuca, Sarah Williams, Swati Tole, James Thommes

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier Gisbert, Geert R. D'Haens, Bu Hayee, Remo Pannacione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

EVALUATION OF PAIRED AND SEPARATED ENDOSCOPIC READS AT BASELINE AND WEEK 14 IN THE EXPLORATORY BERGAMOT INDUCTION COHORT

Young S. Oh

Evaluation of Paired and Separated Endoscopic Reads at Baseline and Week 14 in the Exploratory BERGAMOT Induction Cohort

Daniel S. Mishkin, Stefan Schreiber, Marco Daperno, Young Oh, Fez Hussain, Azra Hassanali, Stuart Lacey, Regan Li, Walter Reinisch

Item 1 - 10 / 12
1
2